Skip to content
My WebMD Sign In, Sign Up

Melanoma/Skin Cancer Health Center

Font Size
A
A
A

ALS Drug Slows Melanoma Growth

Study Shows Riluzole Shrinks Tumors Without Toxic Side Effects
By
WebMD Health News
Reviewed by Louise Chang, MD

new melanoma drug

April 15, 2008 (San Diego) -- A drug used to treat Lou Gehrig's disease appears to curb the growth of melanoma, the most deadly form of skin cancer, a small study shows.

New Jersey researchers studied riluzole, which is used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

Tumors were completely wiped out in three of nine people with advanced melanoma who were given the drug for two weeks.

"Their tumors, which you could see outside the body before treatment, completely disappeared," James Goydos, MD, tells WebMD. Goydos is a surgical oncologist at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in New Brunswick.

In two more patients, imaging scans showed that tumors had shrunk. Three more patients remained stable. One patient got worse, with signs of tumor growth.

The researchers tracked the patients' progress before and after the treatment with biopsies and PET scans, a form of nuclear-medicine imaging typically used to detect cancer.

The results were presented at the annual meeting of the American Association for Cancer Research.

Riluzole Lowers Glutamate Levels

Each year, more than 53,600 people in the U.S. are diagnosed with melanoma, according to the National Cancer Institute (NCI). In the past 30 years, the number of Americans who develop melanoma annually has more than doubled.

In about 70% of cases, people with melanoma develop lesions in body areas that are exposed to the sun. The cancer can then spread to other parts of the body -- typically the lymph nodes first and then other organs.

The new study involved people whose disease had spread, or metastasized, to the lymph nodes.

The work builds on the research team's earlier discovery that melanoma cells release a lot of a substance called glutamate.

Too much glutamate can overstimulate brain cells to the point that they burn out -- a possible explanation of what happens in ALS, says Suzie Chen, PhD, a professor of chemical biology at Rutgers University.

Riluzole, also sold as Rilutek, fights ALS by lowering glutamate levels. "So my collaborators said, let's test it against melanoma. And much to our surprise, the drug slowed the growth rate of melanoma cells [in the test tube]," Chen says.

In animal studies, riluzole again suppressed tumor cell growth and progression, she says. The researchers were then able to secure an NCI grant to perform a new type of first-in-human study; it's designed to validate if a drug will perform as expected in humans -- "to see if you are hitting your targets," Goydos says.

"This is the very first time we have treated melanoma patients with drugs that target [glutamate] and a significant number of patients responded," he says. The only significant side effect was dizziness, according to Chen.

Today on WebMD

Woman checking out tan lines
SLIDESHOW
Cancer Fighting Foods Slideshow
SLIDESHOW
 
what is your cancer risk
HEALTH CHECK
Could Caffeine Help Fight Skin Cancer
VIDEO
 

12 Ways to Protect Your Skin from Melanoma
ARTICLE
precancerous lesions slideshow
SLIDESHOW
 
Do You Know Your Melanoma ABCs
VIDEO
15 Cancer Symptoms Men Ignore
ARTICLE
 

screening tests for men
SLIDESHOW
Vitamin D
SLIDESHOW
 
Is That Mole Skin Cancer
VIDEO
Brilliant sun rays
Quiz
 

WebMD Special Sections